4D Molecular Therapeutics (NASDAQ:FDMT) Stock: Insider Scott Bizily Sells 1,635 Shares

by · The Markets Daily

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) insider Scott Bizily sold 1,635 shares of the stock in a transaction on Friday, October 16th. The stock was sold at an average price of $12.84, for a total transaction of $20,993.40. Following the sale, the insider owned 8,617 shares of the company’s stock, valued at approximately $110,642.28. This represents a 15.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Scott Bizily also recently made the following trade(s):

  • On Wednesday, September 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $13.65, for a total value of $22,317.75.
  • On Tuesday, September 1st, Scott Bizily sold 584 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $14.00, for a total transaction of $8,176.00.
  • On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total transaction of $19,620.00.
  • On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.20, for a total transaction of $19,947.00.

4D Molecular Therapeutics Stock Performance

Shares of 4D Molecular Therapeutics stock traded up $0.81 on Tuesday, reaching $13.10. 718,021 shares of the stock were exchanged, compared to its average volume of 854,704. The firm has a market capitalization of $723.64 million, a PE ratio of -4.98 and a beta of 2.75. 4D Molecular Therapeutics, Inc. has a 1-year low of $6.96 and a 1-year high of $16.93. The business has a fifty day moving average price of $14.02 and a two-hundred day moving average price of $11.55. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). The business had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. As a group, research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of large investors have recently bought and sold shares of the stock. Jupiter Topco LLC acquired a new position in 4D Molecular Therapeutics in the second quarter valued at $76,466,000. Janus Henderson Group PLC lifted its position in 4D Molecular Therapeutics by 13.2% during the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after buying an additional 611,276 shares during the period. BlackRock Inc. acquired a new stake in 4D Molecular Therapeutics in the 2nd quarter worth about $60,463,000. Trails Edge Capital Partners LP purchased a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at about $29,631,296. Finally, Bank of America Corp DE purchased a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at about $14,905,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on FDMT shares. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Bank of America raised their price objective on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday, September 29th. B. Riley Financial reissued a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Cantor Fitzgerald raised shares of 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price objective on the stock in a report on Monday, September 14th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $28.90.

View Our Latest Analysis on 4D Molecular Therapeutics

4D Molecular Therapeutics Company Profile

(Get Free Report)

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.

Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.

Featured Articles